01Prelude Therapeutics reported Q3 EPS of -$0.12, beating the -$0.14 consensus estimate by $0.02 per share on November 16, 2026.
02Revenue came in at $5.6M, significantly missing the $24.2M estimate, indicating a substantial shortfall in top-line performance.
03The stock trades at $3.28 with a market capitalization of $89.1M as of the earnings report date.
04The company has beaten EPS estimates for four consecutive quarters, with Q1 showing the largest surprise at 51.9% above consensus.
Earnings Results
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly earnings results on November 16, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.12, beating the consensus estimate of $-0.14 by $0.02 per share. Revenue came in at $5.6M, missing the estimate of $24.2M.
Company Overview
Prelude Therapeutics's stock moved following the earnings release. The stock currently trades at $3.28 with a market capitalization of $89.1M.
Prelude Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 14% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Prelude Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.